- Home
- CRSP vs CNR Comparison
CRSP vs CNR Comparison
Compare CRSP & CNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- CNR
- Stock Information
- Founded
- CRSP 2013
- CNR 1864
- Country
- CRSP Switzerland
- CNR United States
- Employees
- CRSP N/A
- CNR N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- CNR Coal Mining
- Sector
- CRSP Health Care
- CNR Energy
- Exchange
- CRSP Nasdaq
- CNR Nasdaq
- Market Cap
- CRSP 5.6B
- CNR 4.6B
- IPO Year
- CRSP 2016
- CNR N/A
- Fundamental
- Price
- CRSP $71.48
- CNR $91.72
- Analyst Decision
- CRSP Buy
- CNR Strong Buy
- Analyst Count
- CRSP 18
- CNR 5
- Target Price
- CRSP $72.59
- CNR $97.40
- AVG Volume (30 Days)
- CRSP 2.6M
- CNR 768.3K
- Earning Date
- CRSP 11-04-2025
- CNR 11-15-2025
- Dividend Yield
- CRSP N/A
- CNR 0.43%
- EPS Growth
- CRSP N/A
- CNR N/A
- EPS
- CRSP N/A
- CNR 0.51
- Revenue
- CRSP $38,050,000.00
- CNR $3,275,589,000.00
- Revenue This Year
- CRSP N/A
- CNR $92.77
- Revenue Next Year
- CRSP $388.50
- CNR $9.20
- P/E Ratio
- CRSP N/A
- CNR $181.91
- Revenue Growth
- CRSP N/A
- CNR 47.13
- 52 Week Low
- CRSP $30.04
- CNR $58.19
- 52 Week High
- CRSP $73.95
- CNR $134.59
- Technical
- Relative Strength Index (RSI)
- CRSP 66.62
- CNR 76.81
- Support Level
- CRSP $67.41
- CNR $81.43
- Resistance Level
- CRSP $73.95
- CNR $85.19
- Average True Range (ATR)
- CRSP 3.46
- CNR 3.58
- MACD
- CRSP 0.87
- CNR 1.14
- Stochastic Oscillator
- CRSP 76.46
- CNR 97.44
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About CNR Core Natural Resources Inc. Common Stock
Core Natural Resources Inc is a producer and exporter of coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The principal activity involves mining, preparation, and marketing of thermal coal, sold to power generators.